Nexentis Technologies Inc. (NXTS): M&A transaction — N2OFF closes acquisition of MitoCareX, issuing stock and $700K cash for 100% of biotech

Nexentis Technologies Inc.

Acquired 100% of MitoCareX, a drug discovery company targeting resistant cancers including pancreatic and non-small cell lung cancer.
Consideration: $700,000 cash to SciSparc and ~1.17M shares (40% of N2OFF fully diluted capital) to the Sellers.
Sellers entitled to 30% of N2OFF financing proceeds (capped at $1.6M) for 5 years and milestone issuances up to 25% additional stock.
Board overlap: N2OFF Chairman Amitay Weiss and Director Liat Sidi also serve on SciSparc's board.

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Nexentis Technologies Inc. completed an acquisition involving SciSparc Ltd, Dr. Alon Silberman, and Prof. Ciro Leonardo Pierri (collectively, the Sellers) (closed 2025-10-20).

Action: acquisition
Counterparty: SciSparc Ltd, Dr. Alon Silberman, and Prof. Ciro Leonardo Pierri (collectively, the Sellers)
Closing: 2025-10-20

Exact text from the filing

On October 20, 2025, upon the satisfaction of the remaining closing conditions in the Agreement, the Acquisition closed (the "Closing").

View on SEC.gov

Browse all m&a transactions →

Nexentis Technologies Inc. filing history →

Source: SEC EDGAR

accession 0001493152-25-019064

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.